tiprankstipranks
iRadimed reports Q4 adjusted EPS 32c vs. 33c last year
The Fly

iRadimed reports Q4 adjusted EPS 32c vs. 33c last year

Reports Q4 revenue $14.9M vs. $11.9M last year. "Iradimed continues a sixth consecutive quarter of reaching record revenue. It’s very rewarding to be part of such growth and witness continued strength in our operating performance, as evidenced once more by our recent fourth quarter and year-ended December 31, 2022, results. Such a performance also allows us to again return value to our shareholders through a special cash dividend. We ended the year on December 31, 2022, with $57.9 million in cash and cash equivalents on our balance sheet and no debt. We believe our remaining cash, after the dividend payout, and future cash flows remain sufficient to fund our operations and investments for our planned growth. Our position in the market grows stronger each quarter, a trend we see continuing. We will continue to operate our business with the same focus on top-line growth and increasing profits as stated in our financial guidance provided earlier this year," said Roger Susi, President, Chief Executive Officer, and Chairman of the Company’s Board of Directors.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IRMD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles